📗 Cite This Artifact
Adenosine A2B Receptor Neurons
Adenosine A2B Receptor Neurons
Overview
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Adenosine A2B Receptor Neurons</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Adenosine A2B Receptor Neurons</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
Adenosine A2B Receptor Neurons
Overview
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Adenosine A2B Receptor Neurons</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Adenosine A2B Receptor Neurons</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
The adenosine A2B receptor (A2BR, ADORA2B) is a G protein-coupled receptor that binds adenosine with low affinity and mediates cellular responses to elevated extracellular adenosine concentrations. Unlike the high-affinity A1 and A2A receptors, A2B receptor activation occurs primarily under pathological conditions where adenosine levels are elevated, such as ischemia, inflammation, or metabolic stress. This property positions A2B receptors as critical sensors of cellular distress and important modulators of neuroinflammatory and regenerative responses in neurodegenerative diseases.
Neurons expressing the A2B receptor represent a unique population with distinct functional properties. While A2B receptor expression is relatively low in the healthy central nervous system, it becomes dramatically upregulated under pathological conditions, making it a potential biomarker and therapeutic target in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions. Understanding the role of A2B-expressing neurons provides insight into endogenous neuroprotective mechanisms and opportunities for pharmacological intervention.
Receptor Biology
Molecular Structure and Pharmacology
The adenosine A2B receptor is a 332-amino acid G protein-coupled receptor (GPCR) encoded by the ADORA2B gene located on chromosome 17p12-p11. Like all adenosine receptors (A1, A2A, A2B, A3), A2B possesses the classic seven transmembrane domain structure characteristic of GPCRs:
- Transmembrane domains: Seven α-helices (TM1-TM7) spanning the plasma membrane
- Extracellular loops: Three loops (ECL1-ECL3) involved in ligand binding
- Intracellular loops: Three loops (ICL1-ICL3) coupling to G proteins
- C-terminal tail: Intracellular domain involved in receptor desensitization and signaling
A2B receptor has the lowest affinity for adenosine among adenosine receptors, with an EC50 in the micromolar range (compared to nanomolar for A1 and A2A). This low affinity means A2B is preferentially activated under conditions of high adenosine, such as:
- Ischemia and hypoxia
- Inflammation and tissue injury
- Metabolic stress
- Intense neural activity
- BAY 60-6583: Selective A2B agonist used experimentally
- NECA (5'-N-ethylcarboxamidoadenosine): Non-selective adenosine analog
- ATL-146e: A2B-selective agonist with potential therapeutic applications
- MRS1754: Selective A2B antagonist
- PSB-603: Potent A2B antagonist
- CVT-6883: A2B antagonist developed for pulmonary diseases
- Alloxazine: Non-selective A2B antagonist
Signaling Pathways
A2B receptor couples primarily to Gs proteins, activating adenylate cyclase and increasing intracellular cAMP. However, it can also couple to Gq proteins, activating phospholipase C (PLC) pathways:
Gs-coupled signaling:
- ↑ cAMP → PKA activation
- ↑ CREB phosphorylation
- Modulation of ion channel function
- Regulation of gene transcription
- ↑ IP3 and DAG
- Calcium release from intracellular stores
- PKC activation
- Activation of MAPK pathways
The dual coupling allows A2B receptors to mediate diverse cellular responses depending on cellular context and co-expressed proteins.
Receptor Regulation
Transcriptional regulation:
- NF-κB-mediated upregulation during inflammation
- HIF-1α stabilization under hypoxia
- CREB-dependent transcription
- Phosphorylation by GRK and PKA
- β-arrestin recruitment and receptor internalization
- Receptor trafficking to the cell surface
- Rapid desensitization via GRK-mediated phosphorylation
- β-arrestin-dependent internalization
- Long-term downregulation with chronic agonist exposure
Cellular Distribution in the CNS
Neuronal Expression
A2B receptor expression in neurons is relatively sparse under normal conditions but becomes more prominent in specific neuronal populations under pathological states:
Cortical neurons:
- Layer 2/3 pyramidal neurons show A2B expression in human cortex
- Interneurons, particularly parvalbumin-positive cells, express A2B
- Expression increases in AD and related dementias
- CA1 pyramidal neurons exhibit A2B expression
- Dentate gyrus granule cells show upregulation in epilepsy and AD
- Hippocampal interneurons are A2B-positive
- Basal ganglia neurons express A2B, particularly in PD
- Thalamic relay neurons show A2B immunoreactivity
- Hypothalamic neurons, especially those involved in energy homeostasis
- Locus coeruleus noradrenergic neurons express A2B
- Raphe serotonin neurons show A2B regulation
- Motor neurons in the spinal cord
Glial Expression
A2B receptor expression is more prominent in glial cells:
Astrocytes:
- A2B is highly expressed in astrocytes, particularly in regions of injury
- Astrocytic A2B mediates pro-inflammatory and protective responses
- Regulates astrocyte proliferation and gliosis
- Microglial A2B expression increases dramatically in neurodegenerative conditions
- A2B signaling modulates microglial activation state
- Can promote both pro-inflammatory and anti-inflammatory phenotypes
- A2B expression in oligodendrocyte precursors
- Role in remyelination and oligodendrocyte regeneration
- Involvement in white matter pathology
Signaling Mechanisms in Neurons
cAMP-Dependent Signaling
The primary signaling pathway for neuronal A2B receptors involves cAMP elevation:
Ion channel modulation:
- Reduced potassium channel activity via PKA phosphorylation
- Modulation of NMDA receptor function
- Regulation of voltage-gated calcium channels
- CREB phosphorylation and transcriptional activation
- Upregulation of neuroprotective genes
- Anti-apoptotic signaling
- Modulation of neurotransmitter release
- Regulation of synaptic plasticity
- Effects on long-term potentiation (LTP)
Calcium Signaling
A2B receptor coupling to Gq pathways enables calcium signaling:
- IP3-mediated calcium release from endoplasmic reticulum
- Activation of calcium-dependent kinases
- Modulation of neuronal excitability
- Regulation of gene transcription via calcium-dependent pathways
Cross-talk with Other Receptors
A2B receptors exhibit significant cross-talk with other signaling systems:
Adenosine receptors:
- Cross-talk with A2A receptors (heterodimerization reported)
- Antagonistic interaction with A1 receptors
- Additive effects with A3 receptors
- Interaction with metabotropic glutamate receptors
- Cross-talk with muscarinic acetylcholine receptors
- Dopamine receptor interactions in the basal ganglia
- Modulation of NMDA receptor function
- Interaction with GABA receptors
- Regulation of AMPA receptor trafficking
Pathophysiology in Neurodegenerative Diseases
Alzheimer's Disease
A2B receptor signaling has complex and context-dependent roles in AD:
Amyloid pathology:
- A2B activation promotes amyloid-β clearance in cellular models
- Enhances microglia-mediated phagocytosis
- May reduce amyloid deposition in animal models
- Limited evidence for direct A2B-tau interactions
- Indirect effects through modulation of kinase/phosphatase activity
- A2B has pro-inflammatory effects in early AD
- Promotes cytokine production by microglia
- May contribute to chronic neuroinflammation
- A2B signaling affects hippocampal plasticity
- Modulates memory consolidation
- Some evidence for cognitive enhancement in animal models
- Selective A2B agonists have been explored for AD
- Concern about pro-inflammatory effects
- Need for careful timing of intervention
Parkinson's Disease
A2B receptors play significant roles in PD pathophysiology:
Dopaminergic neurons:
- A2B expression increases in substantia nigra in PD
- May provide neuroprotection against dopaminergic toxicity
- Modulates mitochondrial function
- Promotes microglial activation in PD
- Contributes to chronic neuroinflammation
- May exacerbate dopaminergic neuron loss
- A2B expressed in noradrenergic neurons
- May modulate norepinephrine release
- Related to LC pathology in PD
- A2B antagonists explored for anti-inflammatory effects
- Combined A2A/A2B targeting considered
- Need for more selective compounds
Amyotrophic Lateral Sclerosis
A2B receptor involvement in ALS is increasingly recognized:
Motor neurons:
- A2B expression increases in spinal cord motor neurons in ALS
- May affect excitotoxicity
- Role in energy metabolism
- Microglial A2B promotes neuroinflammation
- Astrocytic A2B affects motor neuron survival
- Oligodendrocyte A2B in white matter changes
- A2B antagonists as anti-inflammatory agents
- Need for blood-spinal barrier penetration
- Early intervention may be critical
Multiple Sclerosis and Demyelination
A2B receptors have particularly important roles in demyelinating diseases:
Oligodendrocyte precursors:
- A2B promotes OPC proliferation
- Enhances differentiation into mature oligodendrocytes
- May promote remyelination
- A2B affects T-cell function
- Modulates B-cell activity
- Reduces autoimmunity
- A2B agonists for promoting remyelination
- Combined immunomodulatory and regenerative effects
- Currently experimental
Stroke and Ischemia
A2B receptors are particularly important in cerebral ischemia:
Ischemic cascade:
- Adenosine levels rise dramatically during ischemia
- A2B activation provides neuroprotective signals
- Reduces infarct size in animal models
- Anti-apoptotic signaling via cAMP/PKA
- Anti-inflammatory effects
- Promotion of angiogenesis
- Enhancement of cerebral blood flow
- Preconditioning effects
- Post-ischemic intervention potential
- Time-limited neuroprotection
Functional Consequences of A2B Expression
Modulation of Neuronal Excitability
A2B receptor activation affects neuronal excitability through multiple mechanisms:
Potassium channels:
- PKA-dependent phosphorylation reduces potassium currents
- Increases neuronal firing frequency
- May contribute to hyperexcitability
- Voltage-gated calcium channel modulation
- Effects on synaptic transmission
- May influence synaptic plasticity
- Modulates glutamate release
- Affects GABAergic signaling
- Bidirectional effects depending on brain region
Effects on Neuroplasticity
A2B signaling influences various forms of synaptic plasticity:
Long-term potentiation:
- Facilitates LTP in hippocampal CA1
- Requires cAMP/PKA signaling
- May involve NMDA receptor modulation
- Can facilitate LTD in some contexts
- Dependent on Gq signaling pathways
- Role in memory flexibility
- A2B may participate in synaptic scaling
- Modulates activity-dependent gene expression
- Affects neuronal network stability
Neuroprotection and Survival
A2B receptor activation can provide neuroprotective effects:
Anti-apoptotic signaling:
- cAMP/PKA pathway activation
- CREB-mediated anti-apoptotic gene expression
- Mitochondrial protection
- Upregulation of antioxidant enzymes
- Reduced ROS production
- Mitochondrial function preservation
- Enhanced glucose uptake
- Improved energy metabolism
- Astrocyte-neuron metabolic coupling
Inflammatory Modulation
A2B receptors have complex effects on neuroinflammation:
Pro-inflammatory effects:
- Promotes cytokine production
- Enhances microglial activation
- May exacerbate chronic inflammation
- Can reduce some inflammatory responses
- Promotes resolution of inflammation
- Modulates adaptive immunity
- Effects depend on timing and duration
- Early vs. late stages differ
- Need for detailed mechanistic understanding
Therapeutic Approaches
A2B Agonists
Rationale:
- Promote neuroprotection
- Enhance amyloid clearance
- Support remyelination
- Provide anti-ischemic effects
- Low receptor selectivity
- Peripheral side effects
- Timing of intervention critical
- BAY 60-6583 (preclinical)
- ATL-146e (preclinical)
- Various adenosine analogs under development
A2B Antagonists
Rationale:
- Reduce neuroinflammation
- Protect dopaminergic neurons
- Modulate immune responses
- Blood-brain barrier penetration
- Selectivity over A2A
- Chronic vs. acute effects
- MRS1754 (research use)
- PSB-603 (research use)
- CVT-6883 (pulmonary, not CNS-penetrant)
Adjunctive Therapies
A2B-targeting therapies may be combined with:
- Dopaminergic therapies in PD
- Anti-amyloid therapies in AD
- Anti-glutamatergic approaches in ALS
- Immunomodulatory therapies
Biomarkers and Diagnostic Applications
Imaging
- PET ligands for A2B receptors under development
- MRI approaches for A2B-related changes
- Functional imaging of A2B-dependent processes
Fluid Biomarkers
- CSF adenosine levels
- A2B-dependent gene expression
- Cytokine profiles reflecting A2B activity
Clinical Correlates
- Disease severity and progression
- Treatment response prediction
- Biomarker combinations for patient stratification
Research Methods and Tools
Genetic Models
- Adora2b knockout mice: Constitutive and conditional knockout lines available
- Reporter mice: A2B-Cre driver lines for cell-type-specific manipulation
- Humanized models: Expressing human A2B in mouse models
Pharmacological Tools
- Radioligands: [3H]MRS1754 for receptor binding studies
- Fluorescent ligands: For receptor visualization
- Biophysical approaches: FRET, BRET for signaling studies
Experimental Approaches
- Primary neuron cultures: Murine and human neurons
- Organotypic brain slices: For circuit-level studies
- In vivo imaging: Two-photon microscopy of A2B activity
Future Directions
Selective Compound Development
- Improved A2B-selective agonists and antagonists
- Brain-penetrant compounds
- Compounds with optimal pharmacokinetics
Biomarker Development
- Clinical-grade PET ligands
- Fluid biomarker validation
- Patient stratification markers
Clinical Translation
- Target indication selection
- Trial design considerations
- Combination therapy approaches
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [Adenosine Signaling](/mechanisms/adenosine-signaling-neurodegeneration)
- [Neuroinflammation and Microglia](/cell-types/neuroinflammation-microglia)
- [Substantia Nigra Dopaminergic Neurons](/cell-types/substantia-nigra-dopaminergic-neurons)
- [Hippocampal Neurons](/cell-types/hippocampal-neurons)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | cell-types-adenosine-a2b-receptor-neurons-v2 |
| kg_node_id | None |
| entity_type | cell |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-7d7e5404fc94 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'cell-types-adenosine-a2b-receptor-neurons-v2'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-cell-types-adenosine-a2b-receptor-neurons-v2?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Adenosine A2B Receptor Neurons](http://scidex.ai/artifact/wiki-cell-types-adenosine-a2b-receptor-neurons-v2)
http://scidex.ai/artifact/wiki-cell-types-adenosine-a2b-receptor-neurons-v2